Aktie A2JJ69 MOLECURE S.A.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Molecure S.A.

Aktien

A2JJ69

PLONCTH00011

MOC

Markt geschlossen - Warsaw S.E.
Andere Börsenplätze
 17:55:42 07.05.2024 		% 5 Tage % 1. Jan.
14.22 PLN -0.42% Intraday Chart für Molecure S.A. -2.34% -27.08%
22.03. Molecure S.A. meldet ersten Patienten in der OATD-01 Phase 2 KITE-Studie bei Lungensarkoidose CI
16.01. Molecure S.A. gibt bekannt, dass keine Genehmigung für die Durchführung von klinischen Studien der Phase II für das Molekül OATD-01 erteilt wurde I CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis
Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
Poland's Molecure Gets US FDA Clearance for Mid-stage Trial of Potential Pulmonary Sarcoidosis Treatment
Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01
Molecure S.A. announced that it has received PLN 49.968 million in funding
Poland's Molecure Files Investigational New Drug Application with US FDA for Pulmonary Sarcoidosis Drug
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023
Molecure S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
Poland's Molecure Doses First Patient in Cancer Treatment Trial
Molecure Announces First Patient Dosed in Phase I Trial with Novel, First-In-Class Dual Arginase Inhibitor OATD-02 for the Treatment of Cancer
Molecure S.A. Announces Management Changes
Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022
Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2022
Molecure S.A.(WSE:MOC) dropped from S&P Global BMI Index
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022
ONCOARENDI THERAPEUTICS S.A will Change its Name to Molecure S.A
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2JJ69 Aktie
  4. Nachrichten Molecure S.A.
  5. Andere Sprachen